ALEXANDRIA, Va. – A large population-based study suggests that the utility of certain types of biomarkers, known as tumor-infiltrating lymphocytes (TILs), to predict colorectal cancer survival depends on where the tumor originates in the body. Although prior research has shown an association between high TIL density and longer survival for patients with colorectal cancers, according to the authors this study is the first to examine the prognostic impact of TILs in regards to tumor location. The study will be presented at the upcoming 2017 ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando.
ALEXANDRIA, Va. – Researchers have found a link between microbes in the gut (the microbiome) and response to immunotherapy. In the study, the ability of patients with advanced melanoma to respond to PD-1 immune checkpoint inhibitors depended on the presence of a diverse microbiome as well as specific bacterial species. The study will be presented at the upcoming 2017 ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando.
ORLANDO – Five studies exploring key issues in the treatment of genitourinary cancers will be presented at the 2017 Genitourinary Cancers Symposium, taking place February 16-18 at Rosen Shingle Creek in Orlando, Florida. These noteworthy abstracts investigate several approaches to the treatment and management of prostate cancer, bladder cancer, and advanced kidney cancer.
ALEXANDRIA, Va. – A new retrospective analysis suggests that immunotherapy may be less effective in patients who receive antibiotics less than a month before starting treatment. In the study, cancer worsened more quickly in such patients than in those who did not receive antibiotics (median progression-free survival 2.3 months vs. 8.1 months). The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.
ALEXANDRIA, Va. – Early findings from a new study appear to challenge the current standard practice for immune checkpoint inhibitor therapy – continuing treatment until cancer worsens. Among patients with advanced kidney cancer who stopped PD1/PD-L1 immunotherapy early due to side effects, 42% had a durable response, meaning they were able to remain off additional systemic therapy for 6 months or more. More broadly, this insight may help alleviate some patients’ concerns about the impact of discontinuing immunotherapy. The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.
ALEXANDRIA, Va. – Analysis of free-floating cancer DNA from blood samples has yielded leads for new prostate cancer treatment targets. Using a commercially available “liquid biopsy” test in patients with advanced prostate cancer, researchers found a number of genetic changes in cell-free, circulating tumor DNA (ctDNA). Cell-free ctDNA is tumor DNA that is circulating freely in the patient’s bloodstream. The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.
“ASCO congratulates Representative Tom Price for his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). Secretary Price has a unique opportunity to shape the availability and quality of care for millions of people with cancer and maintain the nation’s leadership in biomedical research."
ALEXANDRIA, Va. – CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that the University of Virginia (UVA) Cancer Center has signed an agreement to participate in the CancerLinQ® platform.
A new study suggests that weight loss could decrease the risk of endometrial cancer in postmenopausal women by as much as 29 to 56%. Researchers observed that the benefit was greatest for obese women who actively worked to lose weight. These findings, which draw from the Women’s Health Initiative (WHI) study data, were published online today in the Journal of Clinical Oncology.
Chicago, Northfield, IL, Bethesda, MD, Alexandria, VA—A new, evidenced-based clinical practice guideline on molecular biomarker testing for patients with colorectal cancer identifies opportunities for improving patient outcomes.
WASHINGTON — A growing number of patients with cancer are benefitting from research advances in immunotherapy, leading the American Society of Clinical Oncology (ASCO) to name immunotherapy as the Society’s advance of the year for a second year in a row. Released today, this year’s report, Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer highlights the expanding role of immunotherapy. Evolving research findings are providing new insights on how to get the optimal results from these relatively new treatments.
SAN DIEGO – Five studies highlighting notable research on survivorship care will be presented at the 2017 Cancer Survivorship Symposium, taking place January 27-28 at the Manchester Grand Hyatt in San Diego. These select abstracts provide a better understanding of the risks associated with treatment and the late effects of cancer.
ALEXANDRIA, Va. – Co-sponsors of the 2017 Genitourinary Cancers Symposium announced today three abstracts to be highlighted in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Monday, February 13, 2017, from 12:00 noon – 1:30 PM (ET).
On January 24, 2017, the Journal of the American Medical Association (JAMA), published “Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014” by Modak et al. The study found that cancer deaths in the U.S. declined by 20 percent from 1980-2014, but there were large differences in cancer mortality as well as areas with unusually higher mortality rates across counties. The following is a statement from Daniel F. Hayes, MD, FACP, FASCO, President of the American Society of Clinical Oncology (ASCO).
ALEXANDRIA, Va. – In the United States, thyroid cancer incidence is increasing more rapidly than any other cancer and is commonly diagnosed at a younger age than most adult cancers. This year, an estimated 64,300 adults in the United States will be diagnosed with the disease.